Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Zuna

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Leukemia|August 6, 2022
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like diseaseJan Zuna, Lenka Hovorkova, Justina Krotka, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
British Journal of Cancer|June 1, 2022
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusionsNicola C Venn, Libby Huang, Lenka Hovorková, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolJanine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Haematologica|May 28, 2016
Characterization of leukemias with ETV6-ABL1 fusionMarketa Zaliova, Anthony V Moorman, Giovanni Cazzaniga, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Hemasphere|April 20, 2026
Biological and clinical characteristics of <i>ETV6</i>::<i>RUNX1</i>-like ALLMarketa Zaliova, Dagmar Schinnerl, Judith M Boer, et al.
Leukemia|June 8, 2022
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapyMatthew Salmon, Helen E White, Hana Zizkova, et al.
Nature Genetics|January 14, 2014
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemiaElli Papaemmanuil, Inmaculada Rapado, Yilong Li, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Leukemia|August 6, 2022
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like diseaseJan Zuna, Lenka Hovorkova, Justina Krotka, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
British Journal of Cancer|June 1, 2022
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusionsNicola C Venn, Libby Huang, Lenka Hovorková, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolJanine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Haematologica|May 28, 2016
Characterization of leukemias with ETV6-ABL1 fusionMarketa Zaliova, Anthony V Moorman, Giovanni Cazzaniga, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Hemasphere|April 20, 2026
Biological and clinical characteristics of <i>ETV6</i>::<i>RUNX1</i>-like ALLMarketa Zaliova, Dagmar Schinnerl, Judith M Boer, et al.
Leukemia|June 8, 2022
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapyMatthew Salmon, Helen E White, Hana Zizkova, et al.
Nature Genetics|January 14, 2014
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemiaElli Papaemmanuil, Inmaculada Rapado, Yilong Li, et al.
Pageof 5